Electrocardiographic (ECG) assessment of patients with acute coronary syndromes (ACS) in the PLATO trial confirms that those receiving ticagrelor are more likely to experience ventricular pauses than ...

A recent ISCHEMIA trial substudy is under scrutiny from surgeons for a data discrepancy, rekindling concerns about reliance on the landmark trial data in the latest coronary revascularization ...

A recent clinical trial reveals how a daily statin pill may prevent heart attacks and strokes in people with HIV. In this substudy of the phase 3 Randomized Trial to Prevent Vascular Events in HIV ...

LIVN's PolySync data show an 84.5% AHI response rate in OSA patients, building on OSPREY results for its aura6000 System.

LOS ANGELES, CA—Among medically managed patients with acute coronary syndromes (ACS) but no ST-segment elevation, prasugrel is associated with lower platelet reactivity than clopidogrel, irrespective ...

August 29, 2010 (Stockholm, Sweden) — Two genetic substudies of the large pivotal trials of the new antiplatelet agents ticagrelor (Brilinta, AstraZeneca) and prasugrel (Effient, Lilly) confirm that ...

The time required for in-clinic drug administration can substantially affect breast cancer patients' quality of life. Subcutaneous (SC) drug administration, as opposed to intravenous (IV), may reduce ...

GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing ...

DURHAM, N.C.--(BUSINESS WIRE)--Istari Oncology, Inc., a clinical-stage biotechnology company focused on development of the novel immune activator lerapolturev for the treatment of solid tumors, today ...